KPF
OBIO icon

K2 Principal Fund’s Orchestra BioMed OBIO Stock Holding History

K2 Principal Fund’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-175,000
Closed -$1.74M – 327
2022
Q2 		$1.74M Buy
+175,000
New +$1.74M 0.19% 114
2022
Q1 		– Sell
-425,541
Closed -$4.29M – 340
2021
Q4 		$4.29M Buy
425,541
+5,192
+1% +$51.2K 0.28% 84
2021
Q3 		$4.16M Buy
420,349
+100,000
+31% +$987K 0.34% 85
2021
Q2 		$3.27M Buy
320,349
+255,443
+394% +$2.64M 0.27% 114
2021
Q1 		$726K Sell
64,906
-134,584
-67% -$1.64M 0.06% 232
2020
Q4 		$2.56M Buy
199,490
+50,490
+34% +$575K 0.22% 132
2020
Q3 		$1.64M Buy
+149,000
New +$1.67M 0.25% 123

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

K2 Principal Fund's OBIO Position: Q3 2022 in Review

K2 Principal Fund sold out of Orchestra BioMed (OBIO) in Q3 2022, closing a stake of 175,000 shares — an estimated $1.74M sold.

K2 Principal Fund first reported a position in OBIO in Q3 2020 and held it in 7 quarters. The position peaked at $4.29M in Q4 2021. 23 funds tracked by Wall St. Rank hold OBIO as of Q3 2022.

  • K2 Principal Fund reported no remaining Orchestra BioMed position as of Q3 2022 after selling out during the quarter.
  • K2 Principal Fund sold 175,000 Orchestra BioMed shares in Q3 2022, an estimated $1.74M.
  • K2 Principal Fund first reported a position in Orchestra BioMed in Q3 2020 and held it in 7 quarters.
  • K2 Principal Fund's Orchestra BioMed position peaked at $4.29M in Q4 2021.
  • 23 funds tracked by Wall St. Rank held Orchestra BioMed as of Q3 2022.

Based on K2 Principal Fund's 13F filing for Q3 2022, filed 14 Nov 2022.